Small cell lung cancer is aggressive and spreads quickly. There are many options for treatment, depending on the type and ...

Freida Gantt, diagnosed with a rare cancer, spent her life caring for others as a certified nursing assistant.

Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.

Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, accounting for more than 80% of all lung ...

The FDA has granted accelerated approval to datopotamab deruxtecan (Datroway) for adults with locally advanced or metastatic non-small cell lung cancer that carries an EGFR mutation and has progressed ...